Effects of Modified Constraint-Induced Movement Therapy and Mirror Therapy in Hemiplegic Stroke (NCT07668349) | Clinical Trial Compass
RecruitingNot Applicable
Effects of Modified Constraint-Induced Movement Therapy and Mirror Therapy in Hemiplegic Stroke
Turkey (Türkiye)16 participantsStarted 2026-02-19
Plain-language summary
The purpose of this study is to investigate and compare the effects of Modified Constraint-Induced Movement Therapy (mCIMT) and Mirror Therapy (MT) on upper extremity motor functions, activity participation, and independence in daily living activities among hemiplegic stroke patients. Participants diagnosed with stroke will be randomly assigned to intervention groups. The study aims to determine which therapeutic modality provides a higher contribution to the functional recovery of the paretic upper limb and overall quality of life.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \* Diagnosis: Confirmed first ischemic or hemorrhagic stroke with clinical and neurological evaluation.
* Time Since Stroke: 3 to 24 months post-stroke onset.
* Hemiplegia: Significant motor deficit in the affected upper extremity.
* Motor Function Level: Presence of mild to moderate motor impairment in the affected upper extremity (FMA-UE score appropriate for the application of modified CIMT and mirror therapy).
* Cognitive Status: Adequate cognitive capacity to understand and follow the study protocols (Mini-Mental State Examination score of 20 or above).
* Visual Perception: Adequate visual perception to perform mirror therapy.
* Comorbidities: Absence of severe coexisting medical conditions that prevent participation (e.g., uncontrolled cardiovascular diseases, severe psychiatric disorders).
* Prior Treatments: No prior intensive participation in the interventions investigated in this study (modified CIMT or mirror therapy).
* Consent: Voluntary agreement to participate and signed informed consent form.
Exclusion Criteria:
* \* Uncontrolled diabetes or other metabolic disorders.
* Progressive non-stroke neurological diseases (e.g., Parkinson's disease, multiple sclerosis).
* Terminal illness or short life expectancy.
* Severe cognitive impairment preventing comprehension or execution of the study protocols (e.g., advanced dementia).
* Severe visual impairment that prevents mirror therapy application (e.g., uncorrected vi…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Fugl-Meyer Assessment-Upper Extremity (FMA-UE)
Timeframe: Baseline (pre-treatment) and 4 weeks (post-treatment)
2
Stroke Rehabilitation Assessment of Movement (STREAM)
Timeframe: Baseline (pre-treatment) and 4 weeks (post-treatment)